Enveric Biosciences announced the issuance of U.S. Patent No. 12,492,179, titled "Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives." The patent covers compositions and methods of treatment for novel molecules aimed at addressing mental health disorders. The protected compounds are designed to target neuropsychiatric, neurological, and addiction disorders, with the goal of improving efficacy and reducing side effects compared to existing treatments. The strengthened intellectual property portfolio provides Enveric with additional opportunities for licensing and partnerships in the neuropsychiatric field.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251229833047) on December 29, 2025, and is solely responsible for the information contained therein.